Fentanyl Citrate Articles
Instanyl sets new standard in breakthrough cancer pain, says Nycomed
11 September 2009
NasalFent gives earlier pain relief than IRMS
3 June 2009
NasalFent gives cancer-pain relief in five min
11 May 2009
CHMP meeting sees good news for AZ, but not for Teva
24 April 2009
Cephalon swings back to profit in 3rd qtr
1 December 2008
Archimedes' NasalFent meets Ph III efficacy endpoint
20 October 2008
Archimedes licenses German rights to Molteni's Oramorph
18 August 2008
Cephalon exceeds guidance for 2nd qtr
11 August 2008
Japan stock market week to June 23, 2008
30 June 2008
EC approves Cephalon's Effentora
21 April 2008
Cephalon's 2007 sales beat its expectations
25 February 2008
CHMP issues positive approval opinions
4 February 2008
Barr's 3rd-qtr income falls 26% on Pliva costs
26 November 2007
Cephalon agrees $425M settlement
19 November 2007
Stock Commentary - New York - week to August 27, 2007
3 September 2007
Barr's second-qtr 2007 profit halves to $45.3M
20 August 2007
Cephalon's 2nd-qtr 2007 sales hit $435M
13 August 2007
Sosei completes AD 923 pharmacokinetic study
28 May 2007
Cephalon's 1st-qtr income soars to $75M
14 May 2007
Watson sees a 4th-qtr 2006 net loss of $489M
12 March 2007
Waxman investigates marketing practices
12 March 2007
Barr posts $391M net loss in 4th qtr 2006
12 March 2007
Stock Commentary - New York week to Feb 19, 2007
26 February 2007
Archimedes initiates Ph III Nasalfent trial
5 February 2007
Japan stock market week to Dec 4, 2006
11 December 2006
Cephalon's 3rd-qtr 2006 sales increases 56%
13 November 2006
Stock Commentary - Tokyo week to Oct 2, 2006
9 October 2006
Cephalon swings to profit in 2nd-qtr 2006
14 August 2006
Fentora viewed as approvable by US FDA
10 July 2006
Stock Commentary - New York week to July 3, 2006
10 July 2006
Cephalon's full-year 2005 loss deepens 130%
27 February 2006
Cephalon sees 19% sales jump in 2nd qtr
15 August 2005
Cephalon's sugar-free analgesic nears FDA OK
4 April 2005
Cephalon post record results for 2004
28 February 2005
Cephalon's 3rd-qtr loss grows on charges
15 November 2004
Stock Commentary - New York
16 August 2004
US FTC clears way for Cephalon's acquisition of CIMA
16 August 2004
Cephalon's 1st-qtr sales up 49% to $215M
10 May 2004
Cephalon product sales leap 147%
18 August 2003
Stock Commentary - New York
14 July 2003
Cephalon misses targets in first quarter
19 May 2003
Cephalon turnover rockets in 2nd quarter
12 August 2002
Anesta wins approval for Actiq in UK
12 October 2000
Cephalon to acquire Anesta in $444M deal
18 July 2000
Anesta files MAA for Actiq
20 August 1999
-Anesta Corp promotions
8 April 1999
Wockhardt Gets FDA Approval To Sell Ranitidine In USA
3 December 1998
Anesta Files More Data In Support Of Actiq
11 May 1998
Actiq Should Get FDA Hearing Soon
11 December 1997
Anesta's Actiq "Not Approvable"
19 November 1997
Actiq Backed By FDA Panel
2 October 1997
Anesta Corp Submits NDA To FDA For Actiq
25 November 1996
ORALET APPROVAL IN USA RECOMMENDED
13 September 1993
Showing 1-60 of 60 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
